SCHEMBL2008703

SCHEMBL2008703

O=C(c1ccccc1)c1nccs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.57
SCD O00767 1/20 0.55
RBBP9 O75884 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
ALDH1A1 P00352 4/20 0.52
PLA2G4A P47712 1/20 0.50
CES1 P23141 1/20 0.49
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
LMNA P02545 3/20 0.49
USP2 O75604 1/20 0.49
GLA P06280 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HPGDS O60760 1/20 0.48
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL27504054 0.98 PLA2G7 (0.56) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL28033270 0.82 TBXAS1 (0.54) PLA2G7RBBP9ALDH1A1KMT2AMEN1
SCHEMBL13606930 0.81 PLA2G7 (0.58) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL2155819 0.81 ALDH1A1 (0.48) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL3830939 0.81 MAPT (0.57) PLA2G7RBBP9NPC1RAB9AALDH1A1
SCHEMBL2975694 0.81 RBBP9 (0.57) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL4116720 0.81 RAB9A (0.55) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL175249 0.81 ALDH1A1 (0.67) PLA2G7RBBP9ALDH1A1PLA2G4ACES1
SCHEMBL8772481 0.80 PLA2G7 (0.53) PLA2G7SCDRBBP9NPC1RAB9A
SCHEMBL2420556 0.80 PLA2G7 (0.47) PLA2G7SCDRBBP9NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058701-A Thioether structure-containing targeted PHGDH active molecular probe, preparation method and application thereof 中国药科大学 2025-05-30 CN claimed
EP-4139286-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP claimed
WO-2021214019-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO claimed
CN-104419326-A Slurry composition for chemical mechanical polishing COWON INNOTECH INC 2015-03-18 CN claimed
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 CN claimed
CN-120058701-A Thioether structure-containing targeted PHGDH active molecular probe, preparation method and application thereof 中国药科大学 2025-05-30 CN disclosed
CN-108689960-A 5- benzylidenes -2- phenyl thiazoles ketone compounds and its preparation and application 济南大学 2018-10-23 CN disclosed
US-9869027-B2 Cleaning composition and method of manufacturing metal wiring using the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-16 US disclosed
CN-107041924-A It is a kind of prevent and treat diabetic nephropathy towards medicine compound extract and preparation method thereof 延吉朝耀生物科技有限公司 2017-08-15 CN disclosed
CN-104892640-B Simultaneously [3,2 b] [1,2,4] triazole derivative and the application of the benzoyl thiazole of 2 phenyl 6 石家庄学院 2017-06-23 CN disclosed
CN-104892640-B Simultaneously [3,2 b] [1,2,4] triazole derivative and the application of the benzoyl thiazole of 2 phenyl 6 石家庄学院 2017-06-23 CN disclosed
US-20160230289-A1 CLEANING COMPOSITION AND METHOD OF MANUFACTURING METAL WIRING USING THE SAME SAMSUNG DISPLAY CO LTD (KR) 2016-08-11 US disclosed
EP-1343807-A2 DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS SCHERING CORPORATION (US) 2003-09-17 EP disclosed
US-20020147139-A1 Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2002-10-10 US disclosed
WO-2002048172-A2 DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS SCHERING CORPORATION (US) 2002-06-20 WO disclosed
EP-0772606-A1 SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP disclosed
WO-1996003392-A1 SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed
EP-0458315-A1 Silver halide color photographic light-sensitive material KONICA CORPORATION (JP) 1991-11-27 EP disclosed
CN-86107814-A Preparation is as the method for the thiazolone of cardiotonic drug 1987-09-30 CN disclosed
US-4352804-A ANTIULCER AGENTS, GASTROINTESTINAL DISORDERS ACF CHEMIEFARMA NV (NL) 1982-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147139-A1 Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus PRSS1, PEPD, TMPRSS11D PLA2G7 943/4885SCD 483/4885RBBP9 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.